Prospect of natural products in glioma: A novel avenue in glioma management

Kundu, Moumita; Das, Subhayan; Dhara, Dibakar; Mandal, Mahitosh

doi:10.1002/ptr.6426

Cited by 26 publications

(14 citation statements)

References 109 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glioma is a fatal brain tumor, which is the fourth leading cause of tumor-related death due to its invasive nature, molecular signals and the location of the central nervous system ( 27 ). In addition to causing death, seizures are common symptoms that seriously affect the lives of patients and their families ( 28 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis

et al. 2019

View full text Add to dashboard Cite

Abstract Glioma is the most common brain tumor with high mortality. However, there are still challenges for the timely and accurate diagnosis and effective treatment of the tumor. One hundred and twenty-one samples with grades II, III and IV from the Gene Expression Omnibus database were used to construct gene co-expression networks to identify hub modules closely related to glioma grade, and performed pathway enrichment analysis on genes from significant modules. In gene co-expression network constructed by 2345 differentially expressed genes from 121 gene expression profiles for glioma, we identified the black and blue modules that associated with grading. The module preservation analysis based on 118 samples indicates that the two modules were replicable. Enrichment analysis showed that the extracellular matrix genes were enriched for blue module, while cell division genes were enriched for black module. According to survival analysis, 21 hub genes were significantly up-regulated and one gene was significantly down-regulated. What’s more, IKBIP, SEC24D, and FAM46A are the genes with little attention among the 22 hub genes. In this study, IKBIP, SEC24D, and FAM46A related to glioma were mentioned for the first time to the current knowledge, which might provide a new idea for us to study the disease in the future. IKBIP, SEC24D and FAM46A among the 22 hub genes identified that are related to the malignancy degree of glioma might be used as new biomarkers to improve the diagnosis, treatment and prognosis of glioma.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…6 However, glioma is located in the sensitive central nervous system, so it is difficult for conventional chemotherapy to break through the blood-brain barrier and exert its medicinal properties, which appeals for new treatment strategies. 7 We would explore the potential therapeutic direction by studying the molecular mechanism of glioma, which is of great value for the treatment of glioma.…”

Section: Introductionmentioning

confidence: 99%

<p><em>SNHG1</em> Promotes Malignant Progression of Glioma by Targeting miR-140-5p and Regulating PI3K/AKT Pathway</p>

Cai

Zhang

Xie

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose: To explore the regulatory mechanism of long non-coding RNA small nucleolar RNA host gene 1 (SNHG1) in glioma. Materials and Methods: The expression of SNHG1 and miR-140-5p in glioma tissues and glioma cell lines (LN-18, KNS-81, and KALS-1) was determined, and the effect of the two on cell proliferation, invasion, and PI3K/AKT pathway was analyzed. Results: SNHG1 was overexpressed in glioma tissues, while miR-140-5p was underexpressed in them, and there was a significant negative correlation between SNHG1 and miR-140-5p. In addition, both down-regulation of SNHG1 and up-regulation of miR-140-5p significantly inhibited the malignant proliferation and invasion of glioma, intensified the apoptosis, and also significantly suppressed the activation of the PI3K/AKT pathway. The dual-luciferase reporter assay, RNA pull-down assay, and RIP determination all confirmed that there was a targeting relationship between SNHG1 and miR-140-5p, and there was no difference between KNS-81 and KALS-1 cells transfected with SNHG1+mimics and si-SNHG1+inhibitor and those in the si-NC group with unrelated sequences in terms of cell malignant progression. Conclusion: SNHG1/miR-140-5p axis and its regulation on PI3K/AKT pathway might be a novel therapeutic direction to curb the malignant progression of glioma.

show abstract

“…TCM is considered as good sources of anti‐tumour drug candidates since most of them are multi‐target and low toxic. More importantly, most TCM possess good ability to penetrate blood‐brain barrier, which is particularly benefit in treating gliomas 48 . To date, a large number of TCM databases have been established, 49‐51 providing extensive natural‐compound candidates for the discovery of novel drugs.…”

Section: Discussionmentioning

confidence: 99%

Identification of autophagic target RAB13 with small‐molecule inhibitor in low‐grade glioma via integrated multi‐omics approaches coupled with virtual screening of traditional Chinese medicine databases

et al. 2021

View full text Add to dashboard Cite

Objectives Autophagy, a highly conserved lysosomal degradation process in eukaryotic cells, has been widely reported closely related to the progression of many types of human cancers, including LGG; however, the intricate relationship between autophagy and LGG remains to be clarified. Materials and methods Multi‐omics methods were used to integrate omics data to determine potential autophagy regulators in LGG. The expression of ZFP36L2 and RAB13 in SW1088 cells was experimentally manipulated using cDNAs and small interfering RNAs (siRNA). RT‐qPCR detects RNAi gene knockout and cDNA overexpression efficiency. The expression levels of proteins in SW1088 cells were evaluated using Western blot analysis and immunofluorescence analysis. Homology modelling and molecular docking were used to identify compounds from Multi‐Traditional Chinese Medicine (TCM) Databases. The apoptosis ratios were determined by flow cytometry analysis of Annexin‐V/PI double staining. We detect the number of autophagosomes by GFP‐MRFP‐LC3 plasmid transfection to verify the process of autophagy flow. Results We integrated various omics data from LGG, including EXP, MET and CNA data, with the SNF method and the LASSO algorithm, and identified ZFP36L2 and RAB13 as positive regulators of autophagy, which are closely related to the core autophagy regulators. Both transcription level and protein expression level of the four autophagy regulators, including ULK1, FIP200, ATG16L1 and ATG2B, and LC3 puncta were increased by ZFP36L2 and RAB13 overexpression. In addition, RAB13 participates in autophagy through ATG2B, FIP200, ULK1, ATG16L1 and Beclin‐1. Finally, we screened multi‐TCM databases and identified gallic acid as a novel potential RAB13 inhibitor, which was confirmed to negatively regulate autophagy as well as to induce cell death in SW1088 cells. Conclusion Our study identified the key autophagic regulators ZFP36L2 and Rab13 in LGG progression, and demonstrated that gallic acid is a small molecular inhibitor of RAB13, which negatively regulates autophagy and provides a possible small molecular medicine for the subsequent treatment of LGG.

show abstract

Prospect of natural products in glioma: A novel avenue in glioma management

Cited by 26 publications

References 109 publications

Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis

Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis

<p><em>SNHG1</em> Promotes Malignant Progression of Glioma by Targeting miR-140-5p and Regulating PI3K/AKT Pathway</p>

Identification of autophagic target RAB13 with small‐molecule inhibitor in low‐grade glioma via integrated multi‐omics approaches coupled with virtual screening of traditional Chinese medicine databases

Contact Info

Product

Resources

About